Join to View Full Profile
333 Cottman AvePhiladelphia, PA 19111
Phone+1 215-728-2500
Fax+1 215-728-3639
Dr. Zibelman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2007 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2007
Certifications & Licensure
PA State Medical License 2012 - 2026
IL State Medical License 2007 - 2014
WI State Medical License 2011 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors Start of enrollment: 2015 Dec 11
- Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2017 Jun 12
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Start of enrollment: 2017 Nov 27
- Join now to see all
Publications & Presentations
PubMed
- Comparison of Outcomes Between African American and European American Patients With Metastatic Clear Cell Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors.Jasmeet Kaur, Jill S Hasler, Elizabeth A Handorf, Matthew R Zibelman, Fern Anari
Clinical Genitourinary Cancer. 2025-04-01 - Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma.Yasser Ged, Amina Touma, Luis Meza Contreras, Roy Elias, Joseph Van Galen
Journal of Immunotherapy. 2025-04-01 - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2025-03-20
Press Mentions
Exploring the Potential of Nivolumab and Axitinib in Renal Cell CarcinomaMarch 11th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
